Forgot Password?
Return to Course Listing

CME: Novel and emerging therapies for constipation-predominant irritable bowel syndrome (IBS-C) and Chronic Idiopathic Constipation (CIC)

Activity Description / Statement of Need:

In this online, self-learning activity:

Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. While the precise pathophysiology is still an area of active investigation, it appears to include a neuro-enteric disconnect, leading to intestinal somato-visceral and motor dysfunction. Genetic, immune function, microbiome, psychological, and environmental factors may also predispose patients to develop of IBS. Its prevalence varies according to country and the criteria used to define it. In North America and Europe, it has a 10-15% prevalence, and it varies by country. In the U.S. and Canada, IBS symptoms are 1.5 to 2 times more prevalent among women. Women commonly report abdominal pain and constipation while men report diarrhea. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life. 

Target Audience:

The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology and internal medicine; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.

Commercial Support Disclosure: This program is supported by an educational grant from Abbvie.

This activity is free of charge.

Release Date: June 26, 2022 -- Expiration Date: June 26, 2024

Faculty: Christopher Chang, MD, PhD


Faculty introduction, disclosures

Introduction content: cursory refresher and review of IBS-C

  • Epidemiology
  • Burden of disease and impact on health-related quality-of-life
  • Differential diagnosis and misdiagnosis of IBS-C and CIC

Treatment of IBS-C and CIC

  • Pharmacotherapy and clinical trial findings
    • Initial and adjunctive therapies
    • More recent therapeutic advances
      • Chloride channel activation
      • Guanylate cyclase receptor agonism
      • 5-hydroxytryptamine (serotonin) 4 receptor agonism
      • NHE3 inhibition
    • Supportive care strategies
  • Clinical challenges
    • Refractory cases
    • Real world evidence and ways in which clinical experience differs from clinical trials
  • Barriers to care
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the burden of IBS-C / CIC and their impact on health-related quality-of-life.
  • Discuss the role of recent therapeutic advances in IBS-C / CIC treatment paradigm.
  • Develop a treatment regimen for a patient with IBS-C / CIC.
  • Describe clinical and logistical challenges in the management of IBS-C /CIC.


ACCME Activity #202299597

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-22-035-H01-P. This is an application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Christopher Chang, MD, PhD, Assistant Professor, University of New Mexico School of Medicine, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Abbvie.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Advances in the diagnosis and management of non-alcoholic steatohepatitis (NASH): best practices and emerging therapies

The difficulty with (C.) difficile: guideline updates and optimal identification and treatment strategies

Child and adolescent Crohn’s disease: Updates in medical and nutritional strategies

Closing the gap in the treatment of constipation-predominant irritable bowel syndrome (IBS-C): From recognition to treating the patient